Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Contingent Consideration (Details)

v3.22.2.2
Fair Value Measurements - Contingent Consideration (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jan. 31, 2022
Sep. 30, 2022
Sep. 30, 2022
Dec. 31, 2021
Oct. 06, 2021
Feb. 25, 2019
Fair Value Measurements              
Contingent consideration under RPAs and CPPAs $ 75   $ 75 $ 75 $ 8,075    
Bioasis | Royalty Purchase Agreement              
Fair Value Measurements              
Changes in estimated fair value of contingent consideration       0      
Contingent consideration under RPAs and CPPAs 100   100 100     $ 100
Payments of contingent consideration     0 0      
Affitech | Commercial Payment Purchase Agreement | Regulatory milestones              
Fair Value Measurements              
Contingent consideration under RPAs and CPPAs 0   $ 0 $ 0 $ 8,000 $ 8,000  
Amount of milestone payment $ 3,000 $ 5,000